Concise Review: Isolation and Characterization of Cells from Human Term Placenta: Outcome of the First International Workshop on Placenta Derived Stem Cells

Parolini, Ornella; Alviano, Francesco; Bagnara, Gian Paolo; Bilic, Grozdana; Bühring, Hans Jörg; Evangelista, Marco; Hennerbichler, Simone; Liu, Bing; Magatti, Marta; Mao, Ning; Miki, Toshio; Marongiu, Fabio; Nakajima, Hitoshi; Nikaido, Toshio; Portmann-Lanz, C. Bettina; Venkatachalam, Sankar; Soncini, M.; Stadler, Guido; Surbek, Daniel; Takahashi, Tsuneo; Redl, Heinz; Sakuragawa, Norio; Wolbank, Susanne; Zeisberger, Steffen M.; Zisch, Andreas H.; Strom, Stephen C.

doi:10.1634/stemcells.2007-0594

Cited by 951 publications

(970 citation statements)

References 123 publications

(146 reference statements)

Supporting

Mentioning

904

Contrasting

Unclassified

Order By: Relevance

“…They are immunologically well tolerated, do not form tumors in the recipient and are cells of fetal origin [14,71]. The combination of their immunomodulatory and EC-supporting properties makes them promising tools for blood vessel reconstruction.…”

Section: Discussionmentioning

confidence: 99%

Placental Mesenchymal Stromal Cells Derived from Blood Vessels or Avascular Tissues: What Is the Better Choice to Support Endothelial Cell Function?

König

Weiss

Rossi

et al. 2015

Stem Cells and Development

Self Cite

View full text Add to dashboard Cite

Mesenchymal stromal cells (MSCs) are promising tools for therapeutic revascularization of ischemic tissues and for support of vessel formation in engineered tissue constructs. Recently, we could show that avascular-derived MSCs from placental amnion release soluble factors that exhibit survival-enhancing effects on endothelial cells (ECs). We hypothesize that MSCs derived from placental blood vessels might have even more potent angiogenic effects. Therefore, we isolated and characterized MSCs from placental chorionic blood vessels (bv-MSCs) and tested their angiogenic potential in comparison to amnion-derived avascular MSCs (av-MSCs). bv-MSCs express a very similar surface marker profile compared with av-MSCs and could be differentiated toward the adipogenic and osteogenic lineages. bv-MSCs exert immunosuppressive properties on peripheral blood mononuclear cells, suggesting that they are suitable for cell transplantation settings. Conditioned medium (Cdm) from av-MSCs and bv-MSCs significantly enhanced EC viability, whereas only Cdm from bv-MSCs significantly increased EC migration and network formation (Matrigel assay). Angiogenesis array analysis of av-and bv-MSC-Cdm revealed a similar secretion pattern of angiogenic factors, including angiogenin, interleukins-6 and -8, and tissue inhibitors of matrix metalloproteinase-1 and 2. Enzyme-linked immunosorbent assay analysis showed that, in contrast to av-MSCs, bv-MSCs secreted vascular endothelial growth factor. In direct coculture with bv-MSCs, ECs showed a significantly increased formation of vessel-like structures compared with av-MSCs. With regard to therapeutic treatment, bv-MSCs and particularly their Cdm might be valuable to stimulate angiogenesis especially in ischemic tissues. av-MSCs and their Cdm could be beneficial in conditions when it is required to promote the survival and stabilization of blood vessels without the risk of unmeant angiogenesis.

show abstract

Section: Discussionmentioning

confidence: 99%

Placental Mesenchymal Stromal Cells Derived from Blood Vessels or Avascular Tissues: What Is the Better Choice to Support Endothelial Cell Function?

König

Weiss

Rossi

et al. 2015

Stem Cells and Development

Self Cite

View full text Add to dashboard Cite

show abstract

“…It is composed by a thin epithelial tissue, a basal membrane, and an avascular connective tissue stroma. The amniotic cells share stem cells properties with differentiation capacity, which makes them an excellent candidate for their use in cellular therapy and regenerative medicine [8][9][10] .…”

Section: Introductionmentioning

confidence: 99%

“…These functions are related, in part, to its capacity to synthesize and release biologically active substances, including cytokines and signaling molecules as the tumor necrosis factor, interferon, transforming growth factor (TGF)-a, TGF-b; fibroblastic growth factor, epidermic growth factor, keratinocytes growth factor, hepatic growth factor, the interleukin-4 (IL-4), IL-6, IL-8, metal proteases, b-defensin, prostaglandins, etc 8,9,11 . The purpose of the present study was to compare bone density of the defects treated with the lyophilized amniotic membrane with the collagen membrane using Cone Beam Computed Tomography and bone histomorphometry.…”

Section: Introductionmentioning

confidence: 99%

Bone density of defects treated with lyophilized amniotic membrane versus collagen membrane: a tomographic and histomorfogenic study in rabbit´s femur

et al. 2014

View full text Add to dashboard Cite

Abstract:The aim of this study was to compare bone density of bone defects treated with lyophilizated amniotic membrane (LAM) and collagen membrane (CM) at three and five weeks. Two bone defects of 4mm in diameter and 6mm deep were created in left distal femoral diaphysis of New Zealand rabbits (n=12). The animals were randomly divided into two groups. One of the defects was covered with lyophilized amniotic membrane (Rosa Chambergo Tissue Bank/National Institute of Child Health-IPEN, Lima, Peru) or collagen membrane (Dentium Co, Seoul, Korea). The second one was left uncovered (NC). The rabbits were killed after three and five weeks (three rabbits/period). The results showed a high bone density and defect repair by new bone. The tomographic study revealed that bone density of the defects treated with LAM at three weeks was equivalent to the density obtained with CM and higher density compared with NC (p<0.05). At five weeks, the bone density obtained with LAM was more than the density obtained with CM and NC (p<0.05). The histomorphometric study showed no significant differences between LAM and CM at three and five weeks (p>0.05). The results show that the lyophilizated amniotic membrane provides equal or higher bone density than the collagen membrane.

show abstract

“…MSCs have been derived from many different organs and tissues 4 Evidence has emerged that also different parts of human placenta, umbilical cord, amniotic membrane, as well as umbilical cord blood harbor MSCs. [5][6][7][8][9] These tissues are normally discarded after birth, avoiding ethical concerns. 10 Mechanical as well as enzymatic methods for MSC isolation from different regions of human placenta of different gestational ages were reported (Table 1, see references therein).…”

Section: Introductionmentioning

confidence: 99%

Multipotent mesenchymal stem cells from human placenta: critical parameters for isolation and maintenance of stemness after isolation

Semenov

Koestenbauer

Riegel

et al. 2010

American Journal of Obstetrics and Gynecology

103

View full text Add to dashboard Cite

Concise Review: Isolation and Characterization of Cells from Human Term Placenta: Outcome of the First International Workshop on Placenta Derived Stem Cells

Abstract: Disclosure of potential conflicts of interest is found at the end of this article.

Cited by 951 publications

References 123 publications

Placental Mesenchymal Stromal Cells Derived from Blood Vessels or Avascular Tissues: What Is the Better Choice to Support Endothelial Cell Function?

Placental Mesenchymal Stromal Cells Derived from Blood Vessels or Avascular Tissues: What Is the Better Choice to Support Endothelial Cell Function?

Bone density of defects treated with lyophilized amniotic membrane versus collagen membrane: a tomographic and histomorfogenic study in rabbit´s femur

Multipotent mesenchymal stem cells from human placenta: critical parameters for isolation and maintenance of stemness after isolation

Contact Info

Product

Resources

About